FDA clears first CD20xCD3 bispecific, giving Genentech leg up in a crowded lymphoma R&D field

The first CD20xCD3 bispecific antibody will soon become available in the US following an FDA approval disclosed Thursday night.

Roche and Genentech’s mosunetuzumab was greenlit as a third-line treatment for adults with relapsed or refractory follicular lymphoma. FDA’s accelerated approval of the therapy now branded as Lunsumio comes seven days...

Click to view original post